The Results Are In from Quest Diagnostics®

Tick-Borne Disease: Testing, Timing, and Better Diagnosis

Tick-borne diseases are becoming an increasing concern across the United States, with rising case counts and expanding geographic spread. While Lyme disease remains the most recognized infection, clinicians are now facing a broader range of pathogens and more complex cases involving co-infections. In this episode of The Results Are In from Quest Diagnostics, host Anne Freeman sits down with Dr. Ann Salm, PhD, Director and Medical Science Liaison Lead for Infectious Disease and Immunology at Quest. Together, they walk through the growing burden of tick-borne illness, the environmental and ecological factors driving its rise, and why accurate diagnosis is becoming more challenging. They break down the importance of timing when selecting diagnostic tests, explaining when molecular testing versus serologic testing is most effective. The conversation also explores the evolution of Lyme disease testing, from standard two-tier testing to the modified two-tier approach, and how newer methods can improve early detection. Listeners will also gain insight into co-infections like anaplasmosis, ehrlichiosis, and babesiosis, and how comprehensive testing panels can support better clinical decision-making. The episode highlights how providers can approach testing strategically to improve patient outcomes in an increasingly complex diagnostic landscape. Don’t miss this practical and timely discussion on how testing advancements are shaping the future of tick-borne disease management. Follow Us Twitter @QuestDX [http://twitter.com/QuestDX]  Facebook @QuestDiagnostics [http://www.facebook.com/questdiagnostics?sk=wall] Instagram @QuestDiagnostics [https://www.instagram.com/questdx/] LinkedIn @QuestDiagnostics [https://www.linkedin.com/company/quest-diagnostics] Abbreviations used in episode: CDC: Centers for Disease Control and Prevention IgG: Immunoglobulin G IgM: Immunoglobulin M STTT: Standard Two-Tier Testing MTTT: Modified Two-Tier Testing Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

Exocrine pancreatic insufficiency: Symptoms, risk factors, and the value of pancreatic elastase testing

Exocrine pancreatic insufficiency (EPI) is an underrecognized but clinically significant condition that can lead to malnutrition, weight loss, and long-term complications if left undiagnosed. Fortunately, there's a noninvasive and highly specific test that can help clinicians take the guesswork out of diagnosis. In this episode of The Results Are In, host Jen Jenkins speaks with Dr Elif Nahas, Associate Director of Pathology and Chair of the Gastrointestinal and Liver Resource Committee at Quest Diagnostics. Dr Nahas explains what EPI is, the most common symptoms, and which patients are at highest risk. She also outlines how pancreatic elastase testing works, why it’s reliable even for patients already on pancreatic enzyme replacement therapy, and how to interpret test results accurately. Whether you're a primary care provider or a GI specialist, this episode offers clear insights into why EPI should be on your diagnostic radar and how early identification and treatment can significantly improve patient outcomes. Follow Us Twitter @QuestDX [http://twitter.com/QuestDX]  Facebook @QuestDiagnostics [http://www.facebook.com/questdiagnostics?sk=wall] Instagram @QuestDiagnostics [https://www.instagram.com/questdx/] LinkedIn @QuestDiagnostics [https://www.linkedin.com/company/quest-diagnostics] Abbreviations used in episode: EPI: Exocrine pancreatic insufficiency AGA: American Gastroenterological Association References mentioned in episode:  1. Quest Diagnostics Test Directory – Pancreatic Elastase-1, Fecal: https://testdirectory.questdiagnostics.com/test/test-detail/14693/pancreatic-elastase-1?cc=MASTER [https://testdirectory.questdiagnostics.com/test/test-detail/14693/pancreatic-elastase-1?cc=MASTER] 2. American Gastroenterological Association (AGA): https://gastro.org [https://gastro.org] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

Discovering Prenatal Genetics

The evolution of prenatal genetics is transforming care by supporting clarity, confidence, and a patient-centric approach. In this episode of The Results Are In by Quest Diagnostics, host Lisa Demers is joined by Paul Kezmarsky, Director of Strategy & Solutions in Genetics at Quest. A board-certified genetic counselor, Paul brings over a decade of experience across both clinical and laboratory settings, with a focus on expanding access to care. They explore how prenatal genetic screening has evolved from the days of limited biochemical tests to today’s broader, pan-ethnic screening approaches. They break down how these tests work, what makes them clinically useful, and why clear results supported by expert guidance are essential for providers and their patients. This episode offers a straightforward look at how prenatal genetics is reshaping pregnancy care, making it more proactive, inclusive, and actionable for providers everywhere. Follow Us Twitter @QuestDX [http://twitter.com/QuestDX] Facebook @QuestDiagnostics [http://www.facebook.com/questdiagnostics?sk=wall] Instagram @QuestDiagnostics [https://www.instagram.com/questdx/] LinkedIn @QuestDiagnostics [https://www.linkedin.com/company/quest-diagnostics] Presented by Quest Diagnostics www.questdiagnostics.com [http://www.questdiagnostics.com] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

PFAS: Understanding the Risks and the Role of Testing

Per- and polyfluoroalkyl substances (PFAS), often called “forever chemicals,” have made their way into drinking water, consumer products, and even our bodies. With potential health risks tied to exposure, PFAS have become one of the most pressing public health challenges today. In this episode of The Results Are In from Quest Diagnostics, host Dr Jack Kain speaks with Dr. Sarah Bartock, National Science Director of Drug Monitoring & Toxicology at Quest. Together, they break down what PFAS are, how people are exposed, and the health conditions that have been linked to these chemicals. They also discuss how blood testing—including Quest’s PFAS 9 Panel—can help patients and providers better understand risk and make informed decisions about exposure reduction and health monitoring. Listeners will also hear about emerging research into possible interventions, the limitations of current testing, and the broader challenges of addressing PFAS in the environment. Don’t miss this important conversation that connects environmental science, preventive care, and clinical practice. Follow Us Twitter @QuestDX [http://twitter.com/QuestDX]  Facebook @QuestDiagnostics [http://www.facebook.com/questdiagnostics?sk=wall] Instagram @QuestDiagnostics [https://www.instagram.com/questdx/] LinkedIn @QuestDiagnostics [https://www.linkedin.com/company/quest-diagnostics] Abbreviations used in episode: NHANES: National Health and Nutrition Examination Survey  NASEM: National Academies of Science, Engineering, and Medicine  References mentioned in episode:  1. Møller JJ, Lyngberg AC, Hammer PEC, et al.. Substantial decrease of PFAS with anion exchange resin treatment - A clinical cross-over trial. Environ Int. 2024;185:108497. doi:10.1016/j.envint.2024.108497 2. Ducatman A, Luster M, Fletcher T. Perfluoroalkyl substance excretion: Effects of organic anion-inhibiting and resin-binding drugs in a community setting. Environ Toxicol Pharmacol. 2021;85:103650. doi:10.1016/j.etap.2021.103650   3. Lindell AE, Grießhammer A, Michaelis L, et al. Human gut bacteria bioaccumulate per- and polyfluoroalkyl substances. Nat Microbiol. 2025;10(7):1630-1647.   4. Dzierlenga MW, Keast DR, Longnecker MP. The concentration of several perfluoroalkyl acids in serum appears to be reduced by dietary fiber. Environ Int. 2021;146:106292. doi:10.1016/j.envint.2020.106292 5. Schlezinger JJ, Biswas K, Garcia A, Heiger-Bernays WJ, Bello D. An oat fiber intervention for reducing PFAS body burden: A pilot study in male C57Bl/6 J mice. Toxicol Appl Pharmacol.  2025;495:117188. doi:10.1016/j.taap.2024.117188 6. Tian Y, Luan M, Zhang J, Yang H, Wang Y, Chen H. Associations of single and multiple perfluoroalkyl substances exposure with folate among adolescents in NHANES 2007-2010. Chemosphere. 2022;307(Pt 3):135995. doi:10.1016/j.chemosphere.2022.135995 7. Zhang Y, Mustieles V, Wang YX, Sun Y, Agudelo J, et al.. Folate concentrations and serum perfluoroalkyl and polyfluoroalkyl substance concentrations in adolescents and adults in the USA (National Health and Nutrition Examination Study 2003-16): an observational study. Lancet Planet Health. 2023;7(6):e449-e458. doi:10.1016/S2542-5196(23)00088-8 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.

Screening is the First Line of Defense: Testing for Hepatitis B, Hepatitis C, & HIV

In this episode of Results Are In by Quest Diagnostics, Jen Jenkins is joined by Dr. Meghan W. Starolis, Senior Science Director of Infectious Disease at Quest Diagnostics, to discuss the importance of universal screening for hepatitis B, hepatitis C, and HIV.  Dr. Starolis explains the CDC’s latest recommendations, the real-world impact of co-infections, and why regular testing is critical even for patients without symptoms. She also breaks down how Quest supports clinicians with tools like the HBV Triple Screen panel, which simplifies complex interpretations, and highlights recent innovations in HIV testing, including updated algorithms and clearer reporting for providers. Listeners will also gain insights into what an HIV “blip” means and how Quest is addressing provider feedback to improve patient care. This episode is essential for healthcare professionals and patients alike who want to better understand why screening is the first step in prevention, care, and improved outcomes. Follow Us Twitter @QuestDX [http://twitter.com/QuestDX] Facebook @QuestDiagnostics [http://www.facebook.com/questdiagnostics?sk=wall] Instagram @QuestDiagnostics [https://www.instagram.com/questdx/] LinkedIn @QuestDiagnostics [https://www.linkedin.com/company/quest-diagnostics] Presented by Quest Diagnostics www.questdiagnostics.com [http://www.questdiagnostics.com] Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.